Dr William Creagh Mulford, MD | |
21818 Oakley Road, Avenue, MD 20609 | |
(301) 769-3450 | |
(301) 769-3450 |
Full Name | Dr William Creagh Mulford |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 21818 Oakley Road, Avenue, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609114685 | NPI | - | NPPES |
M05975 | Other | MD | CDS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | D0007747 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr William Creagh Mulford, MD Po Box 39, Avenue, MD 20609 Ph: () - | Dr William Creagh Mulford, MD 21818 Oakley Road, Avenue, MD 20609 Ph: (301) 769-3450 |
News Archive
Cognizant, a leading provider of information technology, consulting, and business process outsourcing services, today announced that it has been selected by CentraState Healthcare System, a leading not-for-profit community health organization, to develop a strategy for transitioning to ICD-10.
Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students. The findings, the researchers say, point to a novel method for early detection of contagious outbreaks.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
People with "prediabetes" (a high risk state for overt type 2 diabetes) who experience a period of normal glucose regulation are 56% less likely to develop diabetes 5∙7 years later, according to a new research Article presented at the American Diabetes Association 72nd Scientific Sessions on Saturday 9 June, and published Online First in The Lancet. This is one of four Articles (all presented at the American Diabetes Association 72nd Scientific Sessions) and a Series of three papers that are part of a special Lancet theme issue on diabetes [1].
› Verified 1 days ago